A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a life sciences company transforming healthcare innovation by accelerating biomarker breakthroughs from discovery to diagnostics using our ultra-sensitive translational research and spatial biology instruments, consumables, and services. We continue to invest in pushing a paradigm shift in healthcare from an emphasis on later-stage treatment to a focus on earlier detection, monitoring, prognosis, and, ultimately, prevention. Our combined platforms have achieved significant commercial adoption with an installed base of over 2,500 instruments and scientific validation with citations in more than 6,200 scientific publications in areas of high unmet medical need and research interest such as neurology, oncology, immunology, and inflammation.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 139M | 139M | 137M | 122M | 106M | 111M |
| Net Income | -107M | -107M | -39M | -28M | -100M | -56M |
| EPS | $-2.51 | $-2.51 | $-1.00 | $-0.75 | $-2.69 | $-1.54 |
| Free Cash Flow | -80M | -80M | -39M | -23M | -60M | -61M |
| ROIC | -37.3% | -36.2% | -11.7% | -8.1% | -27.8% | -12.5% |
| Gross Margin | 46.8% | 46.8% | 60.5% | 60.7% | 43.0% | 58.6% |
| Debt/Equity | 0.00 | 0.42 | 0.23 | 0.22 | 0.21 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -126M | -126M | -53M | -46M | -104M | -57M |
| Operating Margin | -90.4% | -90.4% | -38.3% | -37.6% | -98.8% | -51.1% |
| ROE | -36.2% | -34.2% | -11.7% | -8.0% | -24.9% | -17.1% |
| Shares Outstanding | 43M | 43M | 39M | 38M | 37M | 36M |
Quanterix Corp passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 53.9%.
Quanterix Corp (QTRX) has a 5-year average return on invested capital (ROIC) of -19.3%. This is below average and may indicate limited pricing power.
Quanterix Corp (QTRX) has a market capitalization of $145M. It is classified as a small-cap stock.
Quanterix Corp (QTRX) does not currently pay a regular dividend.
Quanterix Corp (QTRX) operates in the Laboratory Analytical Instruments industry, within the Technology sector.
Quanterix Corp (QTRX) reported annual revenue of $139 million in its most recent fiscal year, based on SEC EDGAR filings.
Quanterix Corp (QTRX) has a net profit margin of -77.1%. The company is currently unprofitable.
Quanterix Corp (QTRX) generated $-80 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Quanterix Corp (QTRX) has a debt-to-equity ratio of 0.42. This indicates a conservatively financed balance sheet.
Quanterix Corp (QTRX) reported earnings per share (EPS) of $-2.51 in its most recent fiscal year.
Quanterix Corp (QTRX) has a return on equity (ROE) of -34.2%. A negative ROE may indicate losses or negative equity.
Quanterix Corp (QTRX) has a 5-year average gross margin of 53.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 10 years of financial data for Quanterix Corp (QTRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Quanterix Corp (QTRX) has a book value per share of $6.93, based on its most recent annual SEC filing.
No recent press releases.